Tiziana Life Sciences #TILS – ASCO Conference – StemPrintER Study Presentation May 14, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to OncotypeDX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of Clinical Oncology (ASCO) Virtual Conference Additional data to be presented validating the SPARE Model for Distant Metastasis Prediction utilizing the Company’s StemPrintER Platform This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London – May…

Tiziana Life Sciences #TILS to present two studies featuring StemPrintER during the American Society of Clinical Oncology (ASCO) Virtual Conference May 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London – May 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announces that two abstracts on the Company’s stem cell biology-based genomic tool, StemPrintER, for the prediction of disease recurrence in breast cancer patients, will be presented at the American Society of Clinical Oncology’s 2020 Virtual Conference. All abstracts, including Abstract #1020, which compares Tiziana’s product to…

After 1 hour 12 minutes, Alan Green talks Blue Prism #PRSM, Shell #RDSB, Braveheart Investments #BRH & Tiziana Life Sciences #TILS on Vox Markets podcast May 7, 2020 – Posted in: Blog, Tiziana Life Sciences (TILS)

Alan Green talks Blue Prism #PRSM, Shell #RDSB, Braveheart Investments #BRH & Tiziana Life Sciences #TILS on Vox Markets podcast. 1 hour 12 minutes in.

Tiziana CEO Kunwar Shailubhai discusses the company’s anti il6 technology to deliver drugs to lungs with Andrew Scott at Proactive Investors May 6, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) CEO and chief scientific officer Kunwar Shailubhai discusses the recent excitement around inhalation and the direct delivery of drugs to lungs. ”It makes a lot of sense”, he says. Shailubhai says he’s pleased he’s covered this approach in his recent patent and in fact was one of the first to do it . ”COVID-19 grows in lungs, that’s where it proliferates and produces inflammation .. that leads to what’s known as…

Tiziana Life Sciences #TILS – Result of GM – Posted in: Tiziana Life Sciences (TILS)

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION At the General Meeting of the Company held at 11.00 a.m. on 6 May 2020, the resolutions to seek additional authorities to issue…

Tiziana Life Sciences #TILS – Major shareholder increases stake – Posted in: Tiziana Life Sciences (TILS)

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : TIZIANA LIFE SCIENCES PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer…

Alan Green talks Barclays #BARC, BP #BP, Tiziana Life Sciences #TILS & Versarien #VRS on UK Investor Magazine podcast April 29, 2020 – Posted in: Tiziana Life Sciences (TILS)

Alan Green discusses Barclays #BARC, BP #BP, Tiziana Life Sciences #TILS & Versarien #VRS with Jonathan Roy on the UK Investor Magazine podcast.

Tiziana Life Sciences #TILS – Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronavirus April 27, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses Combination of nanoparticle-Actinomycin D acting as an anti-viral treatment, with an anti-inflammatory agent may present a potential therapeutic option for COVID-19 patients. New York/London – April 27, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that…

Tiziana Life Sciences #TILS – Acquires Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia – Posted in: Tiziana Life Sciences (TILS)

New York/London – April 24, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that it pursuant to an asset purchase agreement it has acquired all of the intellectual property relating to a nanoparticle-based formulation of Actinomycin D (Act D; a.k.a. Dactinomycin), from Rasna Therapeutics, Inc. (“Rasna”) to expand its pipeline for a consideration of an initial…

Alan Green & Zak Mir discuss Open Orphan #ORPH, Tiziana Life #TILS & Bidstack #BIDS on ShareTalk TV April 24, 2020 – Posted in: Open Orphan (ORPH), Tiziana Life Sciences (TILS)

Alan Green and Zak Mir, Share Talk‘s resident chartist, discuss today’s announcement from Open Orphan Plc #ORPH involving it’s London-based subsidiary HVIVO , plus Tiziana Life Sciences #TILS and it’s TZLS-501 anti IL6 treatment for #COVID1 patients with chronic respiratory conditions, plus Bidstack #BIDS unique platform to serve ads into the huge online gaming market. Link on the image to view. #podcast #disruptive #podcasting #sharetalk

« First
1
2
3
4
5
...
7
Next
Last »